![](/img/cover-not-exists.png)
16830 Results from the open-label treatment period of a long-term proactive management phase III trial using fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam
Lebwohl, Mark, Philippe LACOUR, Jean, Liljedahl, Monika, Lynde, Charles, Mørch, Marie, Snel-Prentø, Anja, Pharma, L.E.O., Thaci, Diamant, Warren, Richard B.Volume:
83
Journal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2020.06.835
Date:
December, 2020
File:
PDF, 243 KB
2020